Citius Oncology, Inc. CTOR Deferred taxes
Deferred taxes at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxExpenseBenefit.
The official record: Citius Oncology, Inc.’s 10-Q, filed February 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s deferred taxes.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s deferred taxes?
- Citius Oncology, Inc. (CTOR) reported deferred taxes of $264.24K in Q4 2025.
- How has Citius Oncology, Inc.'s deferred taxes changed year-over-year?
- Citius Oncology, Inc.'s deferred taxes decreased by 0.0% year-over-year, from $264.24K to $264.24K.
- What is the long-term trend for Citius Oncology, Inc.'s deferred taxes?
- Over 2 years (2023 to 2025), Citius Oncology, Inc.'s deferred taxes has grown at a 35.5% compound annual growth rate (CAGR), from $576K to $1.06M.
- What does deferred taxes mean?
- Represents the change in deferred tax assets and liabilities during the period, reflecting temporary differences between financial reporting and tax reporting. This metric indicates future tax consequences of events already recognized in the financial statements. It is essential for understanding the company's effective tax rate and future cash tax obligations.